Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Merck
Baxter
McKinsey
Moodys

Last Updated: March 26, 2023

NORVASC Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Norvasc patents expire, and when can generic versions of Norvasc launch?

Norvasc is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in NORVASC is amlodipine besylate. There are fifty drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the amlodipine besylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Norvasc

A generic version of NORVASC was approved as amlodipine besylate by APOTEX on May 23rd, 2007.

  Try a Trial

Drug patent expirations by year for NORVASC
Drug Prices for NORVASC

See drug prices for NORVASC

Drug Sales Revenue Trends for NORVASC

See drug sales revenues for NORVASC

Recent Clinical Trials for NORVASC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Overseas Pharmaceuticals, Ltd.Phase 1
Guangzhou Health Start Pharmaceutical Techology Co.,LtdPhase 1
Haitian Group for the Study of Kaposi's Sarcoma and OpportunisticPhase 2

See all NORVASC clinical trials

US Patents and Regulatory Information for NORVASC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viatris NORVASC amlodipine besylate TABLET;ORAL 019787-001 Jul 31, 1992 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viatris NORVASC amlodipine besylate TABLET;ORAL 019787-002 Jul 31, 1992 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viatris NORVASC amlodipine besylate TABLET;ORAL 019787-003 Jul 31, 1992 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NORVASC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viatris NORVASC amlodipine besylate TABLET;ORAL 019787-001 Jul 31, 1992 See Plans and Pricing See Plans and Pricing
Viatris NORVASC amlodipine besylate TABLET;ORAL 019787-003 Jul 31, 1992 See Plans and Pricing See Plans and Pricing
Viatris NORVASC amlodipine besylate TABLET;ORAL 019787-003 Jul 31, 1992 See Plans and Pricing See Plans and Pricing
Viatris NORVASC amlodipine besylate TABLET;ORAL 019787-002 Jul 31, 1992 See Plans and Pricing See Plans and Pricing
Viatris NORVASC amlodipine besylate TABLET;ORAL 019787-001 Jul 31, 1992 See Plans and Pricing See Plans and Pricing
Viatris NORVASC amlodipine besylate TABLET;ORAL 019787-002 Jul 31, 1992 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NORVASC

See the table below for patents covering NORVASC around the world.

Country Patent Number Title Estimated Expiration
Kenya 3778 DIHYDROPYRIDINE ANTI-ISCHAEMIC AND ANTIHYPERTENSIVE AGENTS,PROCESSES FOR THEIR PRODUCTION,AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM See Plans and Pricing
Sweden 8701348 See Plans and Pricing
Egypt 16987 PROCESS FOR PREPARING NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES See Plans and Pricing
Ecuador SP941129 UN PROCEDIMIENTO PARA LA PREPARACION DE LA SAL DE BESILATO DE AMLODIPINA See Plans and Pricing
Norway 864435 See Plans and Pricing
Germany 3761485 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NORVASC

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1915993 300625 Netherlands See Plans and Pricing PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
0503785 CA 2011 00026 Denmark See Plans and Pricing PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0089167 SPC/GB93/046 United Kingdom See Plans and Pricing SPC/GB93/046: 20040307
0678503 C300499 Netherlands See Plans and Pricing PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114
0503785 C300375 Netherlands See Plans and Pricing PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
1915993 C300625 Netherlands See Plans and Pricing PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Boehringer Ingelheim
McKesson
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.